1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2016

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2016’, provides an overview of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)
- The report reviews pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) therapeutics and enlists all their major and minor projects
- The report assesses Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Overview 7
Therapeutics Development 8
Pipeline Products for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Overview 8
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Therapeutics under Development by Companies 9
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Products under Development by Companies 12
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Companies Involved in Therapeutics Development 13
Achillion Pharmaceuticals, Inc. 13
Akari Therapeutics, Plc 14
Alexion Pharmaceuticals, Inc. 15
ChemoCentryx, Inc. 16
Epirus Biopharmaceuticals, Inc. 17
greenovation Biotech GmbH 18
Omeros Corporation 19
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ALXN-1210 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
CCX-168 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Coversin - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
eculizumab biosimilar - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
ET-006 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
GRN-003 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
OMS-721 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Small Molecules to Inhibit Complement Factor D for Acute Hemolytic Uremic Syndrome - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Recent Pipeline Updates 40
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Dormant Projects 48
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Product Development Milestones 49
Featured News and Press Releases 49
Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines and Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial 49
Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays 49
Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting 50
Aug 18, 2015: Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial 51
Jul 23, 2015: FDA Grants "Fast Track" to Omeros' Complement Inhibitor OMS721 for aHUS 53
Apr 14, 2015: European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721 53
Nov 20, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in Atypical Hemolytic Uremic Syndrome Treatment by the FDA 54
Nov 19, 2014: OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients 54
Apr 03, 2014: Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies 55
Mar 10, 2014: Omeros Announces Positive OMS721 Data in Serum from Patients with aHUS 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables
Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Achillion Pharmaceuticals, Inc., H1 2016 13
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Akari Therapeutics, Plc, H1 2016 14
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 15
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by ChemoCentryx, Inc., H1 2016 16
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 17
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by greenovation Biotech GmbH, H1 2016 18
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Omeros Corporation, H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics - Recent Pipeline Updates, H1 2016 40
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Dormant Projects, H1 2016 48

List of Figures
Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Targets, H1 2016 21
Number of Products by Stage and Targets, H1 2016 21
Number of Products by Mechanism of Actions, H1 2016 23
Number of Products by Stage and Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Molecule Types, H1 2016 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...


Download Unlimited Documents from Trusted Public Sources

Healthcare Industry - Analyst Report, December 2016

  • December 2016
    15 pages
  • Hepatitis C  

  • India  

    World  

View report >

TiGenix NV - Company Report, December 2016

  • December 2016
    53 pages
  • Digestive Syste...  

    Blood Disease  

  • Europe  

    United States  

View report >

GSK - Company Report, November 2016

  • November 2016
    90 pages
  • Vaccine  

    Infectious Dise...  

  • World  

    United Kingdom  

    Europe  

View report >

Related Market Segments :

Infectious Disease
Therapy

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.